FiercePharma6d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients ... same treatment class can ...
Yahoo Finance5d
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with polyangiitis (EGPA) as the US Food and Drug Administration (FDA ...
Joplin Globe6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...
Yahoo Finance6d
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients ...
Stockhouse6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s FASENRA ...
PharmiWeb6d
Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
The safety and tolerability profile for Fasenra in the MANDARA trial was consistent with the known profile of the medicine. 4 Approximately half of patients with EGPA have adult-onset severe ...
Investing6d
FDA approves Fasenra for rare vasculitis treatment
WILMINGTON, Del. - AstraZeneca’s Fasenra (benralizumab) has gained U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with eosinophilic granulomatosis with ...
Benzinga.com6d
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
In the trial, nearly 60% of Fasenra-treated patients achieved remission, comparable to GSK's mepolizumab-treated patients. Fasenra is currently approved as an add-on maintenance treatment for ...
Pharmabiz5d
US FDA approves AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
Investing6d
FDA approves Fasenra for rare vasculitis treatment
WILMINGTON, Del. - AstraZeneca’s Fasenra (benralizumab) has gained U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with eosinophilic granulomatosis with ...